Dr. Algazy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5104 Parkview Drive
Haverford, PA 19041Phone+1 215-292-2519- Is this information wrong?
Education & Training
- Johns Hopkins UniversityResidency, Internal Medicine, 1972 - 1974
- University of RochesterResidency, Internal Medicine, 1970 - 1972
- Abington Memorial HospitalInternship, Transitional Year, 1969 - 1970
- Lewis Katz School of Medicine at Temple UniversityClass of 1969
- Johns Hopkins UniversityFellowship, Medical Oncology
- Johns Hopkins UniversityFellowship, Hematology
Certifications & Licensure
- PA State Medical License 1970 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- America's Top Doctors Castle Connolly, 2003-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squam...Surbhi Grover, Nandita Mitra, Fei Wan, John N. Lukens, Sonam Sharma, Jessica Bauman, Farzad Masroor, Roger B. Cohen, Arati Desai, Kenneth M. Algazy, Michelle Alonso-Ba...> ;American Journal of Clinical Oncology. 2016 Oct 1
- 21 citationsInduction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neckJessica Bauman, Corey J. Langer, Harry Quon, Kenneth M. Algazy, Alexander Lin, Arati Desai, Faith Mutale, Jared Weiss> ;Experimental and Therapeutic Medicine. 2013 Apr 1
- 28 citationsA Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell CancerMatthew G. Fury, Eric J. Sherman, Donna Lisa, Neeraj Agarwal, Kenneth M. Algazy, Bruce Brockstein, Corey J. Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan H. K...> ;Journal of the National Comprehensive Cancer Network. 2012 Nov 1
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: